Although log-rank analysis displayed no statistically significant effect of mTOR inhibitors on patient prognosis and disease progression, we believe that mTOR inhibitors can effectively prevent TFE3-RCC progression, which may also be due to the lack of data. The gene discussed is TFE3; the disease is renal cell carcinoma.